Gentamicin 40mg/ml Solution for Injection or Infusion United Kingdom - English - myHealthbox

gentamicin 40mg/ml solution for injection or infusion

wockhardt uk ltd - gentamicin sulfate - solution for injection or infusion - 40mg/ml - antibacterial for systemic use - it is indicated in bacteraemia, urinary tract infections, chest infections, severe neonatal infections and other serious systemic infections due to susceptible organisms, in adults and children including neonates

Gentamicin 80 mg/2 mL Injection BP Australia - English - Department of Health (Therapeutic Goods Administration)

gentamicin 80 mg/2 ml injection bp

pfizer (perth) pty ltd - gentamicin sulfate, quantity: 40 mg/ml - injection, solution - excipient ingredients: disodium edetate; sulfuric acid; sodium hydroxide; water for injections - for treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis.

B. BRAUN GENTAMICIN gentamicin (as sulfate) 80 mg/80 mL injection, intravenous infusion, bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 80 mg/80 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 1.39 mg/ml (equivalent: gentamicin, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

B. BRAUN GENTAMICIN gentamicin (as sulfate) 240 mg/80 mL injection, intravenous infusion, bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 240 mg/80 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

B. BRAUN GENTAMICIN gentamicin (as sulfate) 360 mg/120 mL injection, intravenous infusion, bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 360 mg/120 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Gentamicin 10mg/ml Solution for Injection or Infusion United Kingdom - English - myHealthbox

gentamicin 10mg/ml solution for injection or infusion

wockhardt uk ltd - gentamicin sulfate - solution for injection or infusion - 10 mg/ml - antibacterial for systemic use - it is indicated in bacteraemia, urinary tract infections, chest infections, severe neonatal infections and other serious systemic infections due to susceptible organisms, in adults and children including neonates.

ilium Gentam 100 Injectable Gentamicin Solution Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ilium gentam 100 injectable gentamicin solution

troy laboratories pty ltd - gentamicin as gentamicin sulfate - parenteral liquid/solution/suspension - gentamicin as gentamicin sulfate antibiotic active 100.0 mg/ml - antibiotic & related - cat - not pregnant | dog - not pregnant | horse - not pregnant - bacterial infection | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Gentamicin 40 mg/ml solution for injection or infusion Ireland - English - HPRA (Health Products Regulatory Authority)

gentamicin 40 mg/ml solution for injection or infusion

wockhardt uk limited - gentamicin - solution for injection/infusion - 40 milligram(s)/millilitre - other aminoglycosides; gentamicin